| 摘要 |
Lovastatin, pravastatin, simvastatin, mevastatin, atorvastatin, fluvastatin and cervastatin and derivatives and analogs thereof are known as HMG-CoA reductase inhibitors and are used as antihypercholesterolemic agents. The majority of them are produced by fermentation using microorganisms of different species identified as species belonging to Aspergillus, Monascus, Nocardia, Amycolatopsis, Mucor or Penicillium genus, some are obtained by treating the fermentation products using the methods of chemical synthesis o r they are the products. The present invention relates to a novel crystalline form of the sodium salt of pravastatin, which is known by the chemical name 1- naphthaleneheptanoid acid, 1, 2, 6, 7, 8, 8a-hexahydro-.beta., .delta., 6- trihydroxy-2-methyl-8 (2-methyl-1-oxobutoxy)-, mono sodium salt, which is useful as a pharmaceutical substance, to the method for its production and isolation, to a pharmaceutical formulation containing the crystalline form o f the sodium salt of pravastatin and a pharmaceutical method of treatment. The novel crystalline form of the sodium salt of pravastatin is useful in the treatment of hypercholesterolemia and hyperlipidemia.
|
